In the traditional drug therapy for AD, therapeutic drugs are mainly divided into two categories: N‐methyl‐d‐aspartate glutamate receptor (NMDAR) antagonists that can maintain the normal physiological function of the NMDAR and acetylcholinesterase inhibitors (AChEIs) that can maintain the normal level of acetylcholine (ACh) [5]. This evidence concerns the gene ACHE and Alzheimer disease.